GSK-706769
- Generic Name
- GSK-706769
A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00979771
- Locations
- 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands
GSK706769 Repeat Dose Study
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Other: Placebo
- First Posted Date
- 2008-07-08
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00711386
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
GSK706769 A First Time in Human Study For Males and Females
Phase 1
Terminated
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT00539201
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath